Lunit Awarded Major National Tender in France, Expanding Access to Breast AI in Public Hospitals
Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today anno...
Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions h...
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of V...
Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities
Next-generation AI solution introduces new clinical features and broader disease detection for chest X-rays SEOUL, South Korea, May 28, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the official launch and CE certifi...
Lunit Highlights AI's Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies
SEOUL, South Korea, May 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology (ASCO) ...
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, ...
Lunit to Power Germany's Largest Private Radiology Network with AI Imaging
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics ...
SimonMed Imaging Partners with Lunit to Deliver Best-in-Class AI for Breast Cancer Detection
A Major Leap Forward in Patient Health and the Future of Mammography PHOENIX, April 23, 2025 /PRNewswire/ -- SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers inthe United States, is proud to announce their partnership with Lunit, a global leader in AI-d...
Lunit Study in Radiology Highlights Trust Gap Between Radiologists and AI in Breast Cancer Screening
Despite strong performance from AI, fewer recalls from AI-flagged cases point to challenges in human-AI collaboration SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the p...
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics...
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea, March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-power...
Lunit Secures Multi-Year Contract with UAE's Largest Healthcare Network to Power National AI Breast Cancer Screening Program
Strategic agreement to deploy Lunit INSIGHT MMG across SEHA's extensive healthcare network, analyzing over hundred thousand mammograms over five years SEOUL, South Korea, March 18, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection
Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings without raising recall rates, presenting a game-changing tool for countries relying on single-reader mammography screening SEOUL, South Korea, March 10, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a le...
Lunit Expands Partnership with Saudi Arabia's Largest Medical Group to Deploy AI Chest X-Ray Solution
Following last year's success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical Group, analyzing 1 million chest X-rays over three years SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics an...
Lunit Achieves Milestone at ECR 2025: 13 Oral Presentations Among 15 AI Studies, Demonstrating Unmatched Clinical Impact
* Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a significant milestone in AI-powered radiology research * Key studies demonstrate AI's capability to replace one radiologist in double reading, detect subclinical breast cancer years in advance, an...
Lunit Announces Leadership Transition at Volpara: Craig Hadfield Appointed CEO
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the appointment ofCraig Hadfield as the new CEO of its subsidiary, Volpara Health Technologies. ...
Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has en...
Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology
Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered sol...
New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images
Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, toda...
Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW
Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer d...
